Archive for the Acomplia info category.
Obesity is a condition that arrives when someone put on extra weight to a level so that it becomes a serious health condition and can endanger their health. Obesity is basically the result of eating too many calories without doing required physical activities. It is normally measured with help of BMI (Body Mass Index) for example the ratio of your height to your body weight. BMI of more than 27 indicates that the person might be overweight and BMI of 30 or more is indication of being obese. Obesity Treatment
Obesity treatment can be done via number of ways like diet programmes, physical exercise and of course, prescription drugs like Acomplia, Xenical. Diet programmes and exercise do help in reducing weight buy it works slowly. On the other hand, prescription drugs like Acomplia, Xenical are faster ways to obesity treatment. These are manufactured by renowned pharmaceutical companies and clinically approved for use.
Acomplia (Rimonabant) for Obesity treatment
Acomplia is a prescription drug for obesity treatment. A French pharmaceutical firm, Sanoti-Aventis manufactures Acomplia slimming pills, which have been approved for sale in the UK and many European countries.
Acomplia contains Rimonabant as the active ingredient which works basically by reducing craving and urge to eat and produces a feeling of fullness. It basically acts as a cannabinoid type I (CB1) receptor and works in the brain to produce feelings of fullness even by eating less food. Acomplia works best if you maintain intake of healthy diet along with physical exercise.
Dosage of Acomplia
Acomplia comes in dose of 20mg and in tablet form. It should be taken once a day, in the morning before breakfast. Acomplia is a prescription drug, so you must consult some doctor before you chose to buy acomplia. Doctor’s recommendation is required to check suitability of drug to your current health condition and to avoid any side effects.
Benefits of Acomplia Rimonabant
Apart from helping to achieve weight loss in case of obesity, Acomplia also assists in smoking cessation. Acomplia also has been shown to help improve heart conditions. It also helps lowering the fat, improve cholesterol and sugar levels found in the body and this way it is also a help to diabetic patients. It is being said that Acomplia can help you lose weight and stop smoking simultaneously. The studies have shown dramatic positive results in both smokers and obese patients.
Side Effects of Acomplia
Like any other prescription medication, Acomplia too is associated with certain side effects. Common side effects, besides others, include depression, anxiety, nervousness, dizziness, memory loss, vomiting, Diarrhoea
Precautions to be taken
You also have the option of Acomplia online which contains some online process to get required prescription before you take Acomplia.
However they are certain precautions to be taken. It should not be taken by patients who have decreased liver and kidney function. Acomplia Rimonabant should not be taken by patients who have depressive disorders and people who take antidepressant medicines. Pregnant and breastfeeding women should avoid weight loss medicines to avoid any risk to mother and baby.
You can also buy acomplia online from some online licensed and reliable pharmacies or clinics. In that case, registered medical doctors from such pharmacies examine your condition based on information given by patient in online consultation form. Doctor issues the required prescription only if he finds it suitable for your health condition. However, it can not replace face to face consultation with doctor.
While Merck is wrapping up a series of clinical trials of diet drug Taranabant, which it expects to submit for FDA approval later this year, Pfizer has just launched a new Phase III trial of its diet drug CP-945,598, suggesting it may be considerably further away from being brought to market.
Merck has two Phase III trials –one a two-year Phase III study involving 2,400 patients, the second a one-year Phase III study involving 1,000 patients — of taranabant, a CB-1 receptor inverse agonist, that appear to have been completed in the first two months of this year.
To this point, Merck has provided no information on the results of these studies — and for that matter, still has released no final information from a two-year, 2,400-patient Phase II study that was completed in December.
Meanwhile, Pfizer’s clinical trial program for its drug targeting the same receptor — which unlike taranabant, is a CB-1 receptor antagonist like rimonabant (Acomplia) — appears to be lagging significantly behind.
Pfizer seems to still be recruiting participants for its two-year Phase III study of CP-945,598 — which began back in 2006 — and lists the estimated completion date for this study as August 2009.
Moreover, Pfizer has only recently begun recruiting 850 participants for a one-year Phase III trial of CP-945,598 — which like the Merck one-year trial of taranabant is focused not on weight-loss but on the use of the drug to prevent weight-regain — and this trial is not set for completion until Jan. 2010.
The notoriously close-mouthed Pfizer also has provided no information on results of its earlier Phase II study of CP-945,598, which was completed more than two years ago.
Interestingly, however, both Merck and Pfizer have one-year Phase III studies underway of the use of their CB-1 drugs in treating type 2 diabetics.
The treatment of diabetes as well as obesity seems to be at the heart of the hopes of Sanofi-Aventis for a second try next year at U.S. approval of rimonabant. Sanofi withdrew its original application last summer after a U.S. FDA advisory panel expressed concern over the drug’s depressive side-effects.
With sales of Acomplia (rimonabant) is low in the several dozen countries where it is on the market, Sanofi-Aventis executives had little to say about their pioneering obesity treatment in a report to analysts on Feb. . But that hardly means they have given up on the CB-1 receptor antagonist.
Instead, Sanofi unveiled plans to make at least three presentations at major U.S. and European medical meetings during 2008 on the results of clinical trials of Acomplia as a treatment for heart disease and diabetes.
And as a strong indication that the results Sanofi Aventis is seeing from the diabetes trials continue to look really good, the French company reiterated that it plans to seek for FDA approval of rimonabant (to be called Zimulti in the United States), this time for treatment of diabetes, in 2009.
So where do things stand on the hopes of millions of obese and overweight people that rimonabant would become the next blockbuster pill for treatment of obesity?
Well, Sanofi reported that fourth quarter sales of Acomplia worldwide totaled 21 million Euros (approximately US $30.6 million) — unchanged from the 21 million Euros in sales that Sanofi reported for the third quarter of 2007.
He said results of the ARPEGGIO study, evaluating rimonabant in combination with insulin for treatment of diabetes, will be presented to the American Diabetes Association at its annual meeting in June 2008.
Cluzel also said Sanofi is awaiting further recommendations from the FDA on the tracking during clinical trials of depressive side-effects associated with rimonabant — the problem that led in mid-2007 to Sanofi’s withdrawal of its application to have Zimulti approved for sale as an obesity drug in the U.S.
“As for side effects, we are in conformity with FDA recommendations particularly when it comes to psychiatric effects, suicidal ideas are very much in the limelight, and of course, this applies for the whole class of CB1s as well as for antiepileptic pills and antidepressives as a class,” Cluzel declared.
“So we are waiting to see what the FDA recommendations will be,” he also said.
So Acomplia will be on the american market sooner or later as an weight loss pill or as a pill that treats diabetes.Will hope that happens really soon because millions of people need it!
Lot of people lived very difficult life before and now they are 100 years old.They lived through the horrible wars, suffer and moved so often. So what is the reason behind their longevity? The true is in their ascetic attitude which generates contentment. Health of your body is directly related with your satisfaction. If you are “happy” man you should be in good physical health. More stress and dissatisfaction, slowly ruins anybody out from inside. The same principle applies upon your diet and your eating habbits. You are pushing your body towards obesity if you are not satisfied with amount of food which you are consimung. Whether it is our eating habit or something else - it is harmful for the body. We are not “happy” people in these days and we cannot be, because of our lifestyle. But medicine has developed diet drug as Acomplia. Acomplia is an prescription medication and it is in the market for over fifty years. This medication has Acomplia hydrochloride as its active ingredient. This ingredient generates contentment in the body by stimulation of hypothalamus and neurotransmitter. You can have a control over our appetite. It is a short-term medication and used for a few weeks only, hence users do not get habitual of the medication.The people who are using Acomplia are satisfied with a lower amount of food. Lowering amount of food is an ideal gateway to your diet. As I mentioned - it is only few weeks medication, but it will do miracles, as many people found lately. After couple of weeks you would not be in any need to take this drug anymore.
Acomplia is prescription medication, so you need to make appointment with your doctor. Side effects are mentioned in another part of this website, but side effects disappear automatically once your body adjusts to the medication.
The investigational drug rimonabant has churned up a lot of excitement thanks to its success so far in producing weight loss and smoking cessation during several clinical trials.
In this trial, 1045 individuals with type 2 diabetes were randomized to receive either 5 mg of rimonabant, 20 mg of rimonabant, or placebo. All patients were on non-insulin diabetic therapy (metformin or a sulfonylurea drug). After 1 year, the group taking the higher dose of rimonabant had significant reductions in weight and waist circumference.
They also had significantly reduced hemoglobin A1C levels, a finding that reflects improved glucose control. Finally, they had significantly improved HDL cholesterol and triglyceride levels, and reduced systolic blood pressure.
These results of RIO-Diabetes appear similar to the results reported in earlier trials with rimonabant - but for the first time the effect of this drug now has been documented in patients with diabetes, a group typically particularly resistant to weight loss.
